Loading clinical trials...
Loading clinical trials...
Phase 2 Study Evaluating the Safety, Tolerability and Efficacy of Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab in Patients With Treatment-Resistant Mixed Chimerism or Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia After Allogeneic Stem Cell Transplantation
Conditions
Interventions
Blinatumomab in combination with donor lymphocyte infusion
Locations
1
Germany
Klinikum der Universität München
Munich, Germany
Start Date
June 1, 2019
Primary Completion Date
May 31, 2021
Completion Date
November 30, 2021
Last Updated
March 12, 2024
NCT06735690
NCT06074666
NCT04972942
NCT07295951
NCT06395103
NCT07523555
Lead Sponsor
Ludwig-Maximilians - University of Munich
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions